GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: CCX 354 | CCX-354 | CCX-354-C
                                 
                                                         
                            
                            
                            
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: CCX354 is an orally active CCR1 antagonist that was originally developed by Chemocentryx for anti-inflammatory/immunomodulatory potential. The chemical structure is claimed as Example 16 in patent WO2008147815A1 [1]. The structure in the patent resolves to PubChem CID 25016615, which is a tautomeric representation of the claimed structure.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments | 
| CCX354 is a failed CCR1 clinical lead anti-inflammatory/DMARD class compound, but it can be used as an experimental tool compound to study the effects of CCR1 antagonism in vitro and in vivo as determined in preclinical testing [1]. |